Hemato Oncology Testing Market Size, Share & Industry Analysis, By Products & Services (Assay Kits & Reagents, Services, and Instruments & Platforms), By Cancer Type (Leukemia, Lymphoma, Multiple Myeloma, and Others), By Testing Technology (Flow Cytometry, Fluorescence in Situ Hybridization, Molecular Diagnostics {PCR, NGS, and Others}, Immunohistochemistry, and Others), By End-user (Academic & Research Institutes, Hospitals & Diagnostic Laboratories, and Others), and Regional Forecast, 2026-2034

The global hemato oncology testing market size was valued at USD 4.54 billion in 2025. The market is projected to grow from USD 4.84 billion in 2026 to USD 8.45 billion by 2034, exhibiting a CAGR of 7.2% during the forecast period.

Hemato oncology testing includes lab tests that are used to detect, classify, and monitor blood cancers, such as leukemia, lymphoma, and myeloma. The market growth is attributed to the rising adoption of advanced tests for the detection of blood cancer. In addition, the introduction of advanced and easier-to-run tests is also projected to have a positive impact on market growth. Along with these factors, the rising prevalence of blood disorders and the growing emphasis on preventive care & screening are also driving the market growth.

• For instance, according to a data published by the National Institutes of Health, an estimated 66,890 new cases of leukemia were expected to occur in year 2025 in the U.S.

Furthermore, many key industry players, such as F. Hoffmann-La Roche AG, Abbott, Danaher Corporation, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., and Bio-Rad Laboratories, Inc., operating in the market, are focusing on introduction of technologically advanced products.

HEMATO ONCOLOGY MARKET TRENDS

Rising Adoption of Molecular Diagnostics for Screening Blood Cancer is a Prominent Trend in the Market

Increasing preference for molecular diagnostic tests for screening blood cancer is one of the prominent trend observed in the market. In addition, market players are launching new panels and assays that make these tests more accessible to clinical labs. Certain benefits offered by molecular diagnostics, such as higher accuracy, product availability, and shorter turnaround times, are supporting this market trend.

• For instance, in March 2022, Vela Diagnostics announced launch of its new NGS panel, specifically for screening of blood cancer.

Download Free sample to learn more about this report.

MARKET DYNAMICS

MARKET DRIVERS

Growing Demand for Personalized Cancer Treatment to Boost Market Growth

The market is witnessing rising demand for personalized therapeutics for cancer treatment. Healthcare professionals are focusing on delivering personalized test results to provide accurate, targeted therapies, thereby achieving better outcomes. This creates steady demand for tests that can confirm the cancer type and detect key disease signals over time. Moreover, market players continue to expand their tumor profiling and genomic test portfolios, which supports ongoing test adoption in routine care.

• For instance, in September 2025, Illumina Inc. announced strategic partnerships with pharmaceutical companies to boost its personalized cancer care portfolio.

MARKET RESTRAINTS

High Test Cost and Irregular Reimbursement Issues to Deter Market Growth

The considerable cost of hemato oncology testing products and services, coupled with irregular reimbursement policies, hampers the hemato oncology testing market growth. Advanced hemato-oncology tests can be expensive, and reimbursement rules can differ by country, hospital, or insurer. Further, when coverage is unclear, some hospitals restrict advanced testing to selected patients, which limits volumes. Moreover, smaller labs also avoid adding new test menus due to budget limits, equipment needs, and staffing constraints.

MARKET OPPORTUNITIES

Rising Demand for Advanced Screening Tests in Healthcare Facilities Worldwide to Provide Favorable Market Growth Opportunities

Hospitals and diagnostic labs worldwide are prioritizing the expansion of cancer testing capabilities to reduce send-outs and speed up decisions. In addition, partnerships among these facilities, along with manufacturers, are expected to offer a favorable opportunity for market growth during the forecast period.

• For instance, in September 2023, Roche France, Foundation Medicine, and Gustave Roussy announced a strategic partnership to establish in-house liquid biopsy genomic testing at the hospital.

MARKET CHALLENGES

Maintaining Results Consistency to Pose a Critical Challenge to Market Growth

Maintaining result accuracy and throughput during screening is one of the critical challenges for the market. Different labs may use different platforms, sample handling steps, and reporting formats, which can complicate the comparison of results across sites. Hospitals also want faster turnaround without sacrificing reliability. This creates operational pressure on labs to standardize methods, train staff, and maintain quality checks. As testing becomes more common in routine care, maintaining consistent and easy to interpret results remains a key challenge for hospitals and diagnostic laboratories.

Segmentation Analysis

By Products & Services

Significant Adoption of Assay Reagents and Kits Due to High Test Volume to Accelerate Segmental Growth

Based on the products & services, the market is divided into assay kits & reagents, services, and instruments & platforms.

The assay kits & reagents segment is anticipated to account for the largest global hemato oncology testing market share. The high segmental share is primarily attributed to its repetitive purchases, driven by high test volumes, growing awareness about hemato oncology testing, and active government involvement. In addition, market introduction of new panels is also expected to implicitly augment segment growth.

• For instance, in May 2024, Illumina announced new MRD assay performance work and collaborations highlighted at ASCO 2024, supporting an increased focus on molecular monitoring.

The services segment is anticipated to grow with a CAGR of 7.6% over the forecast period.  

To know how our report can help streamline your business, Speak to Analyst

By Cancer Type

Higher Prevalence and Utilization of Advanced Tests for Lymphoma to Drive Lymphoma Segment Growth

Based on cancer type, the market is segmented into leukemia, lymphoma, multiple myeloma, and others.

In 2025, the lymphoma segment dominated the global market. Lymphoma has a high share, as it includes many subtypes that require accurate classification to guide treatment decisions. Moreover, companies are also developing more lymphoma-focused tools, which enable labs and clinicians to obtain accurate diagnostics.

• For instance, in June 2024, Roche announced the launch of its new test, specifically for B-cell lymphoma. The newly introduced test has high sensitivity.

The multiple myeloma segment is projected to grow at a CAGR of 7.8% over the forecast period. 

By Testing Technology

Technological Advancements in Molecular Diagnostics to Drive Segment Growth

Based on testing type, the market is segmented into flow cytometry, fluorescence in situ hybridization, molecular diagnostics, immunohistochemistry, and others.

In 2025, the molecular diagnostics segment dominated the global market. This growth is driven by its ability to provide more specific disease information that supports therapy decisions and monitoring. In addition, hospitals and diagnostic labs are increasingly utilizing DNA/RNA-based testing to identify relevant markers and track disease changes.

• For instance, in November 2024, Illumina announced expansion of its TruSight Oncology portfolio, supporting broader tumor profiling adoption.

The immunohistochemistry segment is projected to grow at a CAGR of 7.4% over the forecast period.

By End-User

Higher Testing Volumes in Hospitals & Diagnostic Centers to Accelerate the Segment

Based on end-user, the market is segmented into academic & research institutes, hospitals & diagnostic laboratories, and others.

The hospitals & diagnostic laboratories dominated the global market. The segment holds the largest share, as it is the primary point where patients are tested and where treatment decisions are made. Large hospitals process high sample volumes and often expand their test menus to improve turnaround times and reduce send-outs. Furthermore, the segment is set to hold 75.0% share in 2026.

In addition, academic & research institutes are projected to grow at a CAGR of 7.1% during the forecast period.

Hemato Oncology Testing Market Regional Outlook

By geography, the market is categorized into North America, Europe, Latin America, Asia Pacific, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America held the dominant share in 2024, valued at USD 1.75 billion, and maintained its leading position in 2025, with a valuation of USD 1.86 billion. The market in North America is expected to increase due to an extensive rise in the prevalence of blood cancer and an increasing number of product launches. These factors, coupled with strong healthcare and substantial technological advancements, are enabling market growth.

U.S Hemato Oncology Testing Market

Based on North America’s robust contribution and the U.S. dominance within the region, the U.S. market can be precisely estimated at around USD 1.69 billion in 2026, accounting for roughly 34.9% of global hemato oncology testing sales.

Europe

Europe is expected to record a growth rate of 6.7% in the near future, which is the second highest among all regions, and reach a valuation of USD 1.35 billion by 2026. The region is estimated to have awareness programs regarding blood cancer screening and presence of major market players.

U.K Hemato Oncology Testing Market

The U.K. hemato oncology testing market in 2026 is estimated at around USD 0.22 billion, representing roughly 4.5% of global hemato oncology revenues.

Germany Hemato Oncology Testing Market

Germany’s hemato oncology testing market is projected to reach approximately USD 0.30 billion in 2026, equivalent to around 6.3% of global hemato oncology sales.

Asia Pacific

Asia Pacific is estimated to reach USD 1.12 billion in 2026 and secure the position of the third-largest region in the market. In the region, India and China are estimated to reach USD 0.25 billion and USD 0.37 billion, respectively, in 2026.

Japan Hemato Oncology Testing Market

The Japan hemato oncology testing market in 2026 is estimated at around USD 0.19 billion, accounting for roughly 4.0% of global hemato oncology revenues.

China Hemato Oncology Testing Market

China’s hemato oncology testing market is projected to be one of the largest globally, with 2026 revenues expected to reach USD 0.37 billion, representing roughly 7.7% of global hemato oncology sales.

India Hemato Oncology Testing Market

The India hemato oncology testing market in 2026 is estimated at around USD 0.25 billion, accounting for roughly 5.1% of global hemato oncology revenues.

Latin America and Middle East & Africa

The Latin America and the Middle East & Africa regions are likely to experience moderate growth in this market during the forecast period. The Latin America market is set to reach a valuation of USD 0.26 billion in 2026. In the Middle East & Africa, the GCC is set to reach a value of USD 0.05 billion in 2026. The rising prevalence of blood disorders, coupled with increasing investments in novel therapeutics, is accelerating market growth in these regions.

South Africa Hemato Oncology Testing Market

The South Africa hemato oncology testing market is projected to reach around USD 0.02 billion in 2026, representing roughly 0.5% of global hemato oncology revenues.

COMPETITIVE LANDSCAPE

Key Industry Players

Focus on Introduction of New Products with Advanced Technologies by Key Players to Propel Market Progress

The global hemato oncology testing market holds a semi-consolidated market structure, including key players such as F. Hoffmann-La Roche AG, Abbott, Danaher Corporation, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., and Bio-Rad Laboratories, Inc. The significant market share of these companies is due to various strategic activities, such as collaboration among operating entities to advance research activities.

• For instance, in May 2025, Danaher announced its plan to enter into a strategic collaboration to boost its diagnostics development for hematology.

Other prominent players in the global market include Sysmex Corporation, Illumina, Inc., QIAGEN N.V., BD. These companies are projected to prioritize new product launches and collaborations to increase their global market share over the forecast period.

LIST OF KEY HEMATO ONCOLOGY COMPANIES PROFILED

• Hoffmann-La Roche AG (Switzerland)
• Abbott (U.S.)
• Danaher Corporation (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Agilent Technologies, Inc. (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• Sysmex Corporation (Japan)
• Illumina, Inc. (U.S.)
• QIAGEN N.V. (Netherlands)
• BD (U.S.)
• Invivoscribe, Inc. (U.S.)
• Invitae Corporation (U.S.)

KEY INDUSTRY DEVELOPMENTS

• October 2025: Flatiron Health announced launch of its new AI-powered hematology datasets to accelerate clinical trials and assessment of treatment outcomes.
• May 2025: Labcorp announced expansion of its oncology portfolio to boost advanced research and cancer care.
• April 2025: Pillar Biosciences received CMS coverage for its oncoReveal CDx Pan-Cancer Solid tumor IVD Kit.
• September 2023: Adaptive Technologies launched Epic integration for clonoSEQ, allowing clinicians to order and view MRD blood cancer test results directly within Epic’s EHR system.
• March 2023: Servier entered into strategic collaboration with QIAGEN to develop new hemato oncology test.

REPORT COVERAGE

To gain extensive insights into the market, Download for Customization

Report Scope & Segmentation